Literature DB >> 14402218

Vincaleukoblastine. I. Preliminary clinical studies.

M E HODES, R J ROHN, W H BOND.   

Abstract

Entities:  

Keywords:  ALKALOIDS/therapy; ANTINEOPLASTIC AGENTS/pharmacology

Mesh：

Substances：

Year:  1960        PMID： 14402218

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  10 in total

1.  STUDIES ON THE SUPPRESSION OF IMMUNE RESPONSES BY THE PERIWINKLE ALKALOIDS VINCRISTINE AND VINBLASTINE.

Authors:  A C AISENBERG; B WILES
Journal:  J Clin Invest       Date:  1964-12       Impact factor: 14.808

2.  Vincaleukoblastine in the treatment of malignant disease.

Authors:  D M WHITELAW; J M TEASDALE
Journal:  Can Med Assoc J       Date:  1961-09-02       Impact factor: 8.262

3.  Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine.

Authors:  G H Fairley; M J Patterson; R B Scott
Journal:  Br Med J       Date:  1966-07-09

4.  Current concepts of cancer chemotherapy.

Authors:  R J PAPAC; D A WOOD
Journal:  Calif Med       Date:  1962-06

5.  Chemotherapy in Malignant Disease: The Present Position.

Authors:  A E Buckle
Journal:  Postgrad Med J       Date:  1961-06       Impact factor: 2.401

Review 6.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

7.  [Long term treatment of advanced lymphogranulomatosis with vinblastine sulfate].

Authors:  E Schulz; W Jüngling; K Hausmann
Journal:  Klin Wochenschr       Date:  1969-02-15

8.  VINCRISTINE IN THE TREATMENT OF NEOPLASTIC DISEASE.

Authors:  D M WHITELAW; H S KIM
Journal:  Can Med Assoc J       Date:  1964-06-20       Impact factor: 8.262

9.  Clinical experience with vincaleukoblastine sulfate in the treatment of 11 patients with Hodgkin's disease.

Authors:  K R Butler
Journal:  Can Med Assoc J       Date:  1965-10-02       Impact factor: 8.262

10.  VINBLASTINE SULPHATE IN THE TREATMENT OF MALIGNANT DISEASE.

Authors:  N M BLEEHEN; A M JELLIFFE
Journal:  Br J Cancer       Date:  1965-06       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.